• RI - Unifesp
    • Documentos
    • Tutoriais
    • Perguntas frequentes
    • Atendimento
    • Equipe
    • português (Brasil)
    • English
    • español
  • Sobre
    • RI Unifesp
    • Documentos
    • Tutoriais
    • Perguntas frequentes
    • Atendimento
    • Equipe
  • English 
    • português (Brasil)
    • English
    • español
    • português (Brasil)
    • English
    • español
  • Login
View Item 
  •   DSpace Home
  • Escola Paulista de Medicina (EPM)
  • EPM - Artigos
  • View Item
  •   DSpace Home
  • Escola Paulista de Medicina (EPM)
  • EPM - Artigos
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Use of Topical Cannabinomimetic Palmitoylethanolamide in Ocular Surface Disease Associated with Antiglaucoma Medications

Thumbnail
Date
2017
Author
Di Zazzo, Antonio
Roberti, Gloria
Mashaghi, Alireza
Abud, Tulio Batista [UNIFESP]
Pavese, Daniela
Bonini, Stefano
Type
Artigo
ISSN
1080-7683
Is part of
Journal Of Ocular Pharmacology And Therapeutics
DOI
10.1089/jop.2016.0117
Metadata
Show full item record
Abstract
Purpose: Chronic use of topical hypotensive therapies in glaucoma patients leads to chronic inflammation of the ocular surface, which decreases the success rate of long-term glaucoma management. The aim of this study is to evaluate the effect of topical palmitoylethanolamide (PEA) (Defluxa((c))), a well-known anti-inflammatory and analgesic agent, in suppressing the ocular surface inflammation associated with the use of hypotensive eye drops. Methods: In a pilot clinical trial, we enrolled 15 glaucomatous patients who received topical PEA (Defluxa) in addition to the current antiglaucoma drugs, while 15 glaucomatous patients did not receive any additional treatment. At 3 different time points (day 0, 15, and 30), signs of ocular surface involvement, adverse events, visual acuity, and intraocular pressure were assessed. Results: Topical PEA (Defluxa) was effective in increasing the Schirmer test (P<0.05) and the tear film breakup time (T-BUT) (P<0.0001), and improving the conjunctival hyperemia (P<0.0001) by day 30, compared to baseline. Compared to control, by day 15, the conjunctival hyperemia score was significantly decreased in the PEA (Defluxa) group (P<0.01), while the T-BUT and the Schirmer Test achieved a significant improvement by day 30 (P<0.05; P<0.01). Discussion: Our data suggests that topical PEA (Defluxa) is a safe, effective, and generally well-tolerated treatment to prevent or suppress ocular surface inflammation attributable to chronic glaucoma treatment.
Citation
Journal Of Ocular Pharmacology And Therapeutics. New Rochelle, v. 33, n. 9, p. 670-677, 2017.
Keywords
palmitoylethanolamide
dry eye
glaucoma
inflammation
ocular surface
antiglaucoma drugs
Sponsorship
Ministry of Health
Fondazione Roma
URI
https://repositorio.unifesp.br/handle/11600/58302
Collections
  • EPM - Artigos [16058]

DSpace software copyright © 2002-2016  DuraSpace
Contact Us
Theme by 
Atmire NV
 

 

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsBy Submit DateThis CollectionBy Issue DateAuthorsTitlesSubjectsBy Submit Date

My Account

Login

Statistics

View Usage Statistics

DSpace software copyright © 2002-2016  DuraSpace
Contact Us
Theme by 
Atmire NV